HK2 and hepatocellular carcinoma: lornitamine, 3-Bromopyruvate, and 2-deoxyglucose inhibit glycolysis by targeting HK2 in glioblastoma and hepatocellular carcinoma and promoting chemo-sensitivity [34–36].